The Effect of Bevacizumab-Related Hypertension on the Prognosis of Patients with Colorectal Cancer and Non-Small Cell Lung Cancer

被引：0
|
作者：
Pan, Juhua [1 ]
Zheng, Liangda [2 ]
Liu, Binghui [1 ]
You, Shuqing [1 ]
Zheng, Weizhi [1 ]
机构：
[1] Taizhou First Peoples Hosp, Dept Pathol, Taizhou 318020, Zhejiang, Peoples R China
[2] Taizhou First Peoples Hosp, Dept Hematol, Taizhou 318020, Zhejiang, Peoples R China
来源：
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES | 2022年 / 84卷
关键词：
Bevacizumab; hypertension; colorectal cancer; non-small cell lung cancer; prognosis;
D O I：
10.36468/pharmaceutical-sciences.spl.448
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
To study and analyze the effect of bevacizumab-related hypertension on the prognosis of patients with colorectal cancer and non-small cell lung cancer. The study randomly selected 100 colorectal cancer patients and 100 non-small cell lung cancer patients who received therapy in our hospital from October 2019 to October 2021. Among them, adopted intervention for 100 colorectal cancer patients with bevacizumab combined with cytotoxic drug chemotherapy and adopted intervention for 100 non-small cell lung cancer patients with bevacizumab combined with standard chemotherapy. Bevacizumab treatment has better therapeutic effect of hypertension on colorectal cancer patients than non-small cell lung cancer patients. Compared with colorectal cancer patients who received bevacizumab treatment, non-small cell lung cancer patients under bevacizumab treatment caused more adverse reactions. Among 100 colorectal cancer patients, the number of patients with bevacizumab-related hypertension in grade 1, grade 2 and grade 3 were 45, 12 and 23 respectively. Among 100 non-small cell lung cancer patients, the number of patients with bevacizumab-related hypertension in grade 1, grade 2 and grade 3 were 44, 25 and 20 respectively. Bevacizumab-related hypertension can improve the prognosis and efficacy of colorectal cancer and non-small cell lung cancer patients.
引用
收藏
页码：21 / 24
页数：4
相关论文
共 50 条
  • [31] Molecular gene signature and prognosis of non-small cell lung cancer
    Huang, Poyin
    Cheng, Chiou-Ling
    Chang, Ya-Hsuan
    Liu, Chia-Hsin
    Hsu, Yi-Chiung
    Chen, Jin-Shing
    Chang, Gee-Chen
    Ho, Bing-Ching
    Su, Kang-Yi
    Chen, Hsuan-Yu
    Yu, Sung-Liang
    ONCOTARGET, 2016, 7 (32) : 51898 - 51907
  • [32] Effect of aspirin on PET parameters in primary non-small cell lung cancer and its relationship with prognosis
    Chen, Jinghua
    Xia, Junxian
    Huang, Jiacheng
    Xu, Ruilian
    BMC CANCER, 2020, 20 (01)
  • [33] Imprinted Genes Predict Non-Small Cell Lung Cancer Prognosis
    Zhou, J.
    Cheng, T.
    Li, X.
    Wang, X.
    Si, H.
    Zhao, P.
    Yung, R.
    Shen, R.
    Yu, H.
    Lu, S.
    Huang, W.
    Zhou, N.
    Bai, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S705 - S705
  • [34] Intracameral bevacizumab administered for non-small cell lung cancer metastasis to iris
    Schell, Jonathan C.
    Koenig, Steven B.
    Bastin, Kenneth
    Wirostko, William J.
    CLINICS AND PRACTICE, 2011, 1 (02) : 74 - 75
  • [35] Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab
    Gray, Jhanelle
    Murren, John
    Sharma, Anupama
    Kelley, Scott
    Detterbeck, Frank
    Bepler, Gerold
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (06) : 571 - 573
  • [36] Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer
    Hamada, Shohei
    Ichiyasu, Hidenori
    Ikeda, Tokunori
    Inaba, Megumi
    Kashiwabara, Kosuke
    Sadamatsu, Tomoki
    Sato, Nahoko
    Akaike, Kimitaka
    Okabayashi, Hiroko
    Saruwatari, Koichi
    Tomita, Yusuke
    Saeki, Sho
    Hirata, Naomi
    Yoshinaga, Takeshi
    Fujii, Kazuhiko
    BMC PULMONARY MEDICINE, 2019, 19 (1)
  • [37] Bowel perforation in non-small cell lung cancer after bevacizumab therapy
    Elisabeth Schellhaas
    Christoph Loddenkemper
    Alexander Schmittel
    Heinz-J. Buhr
    Uwe Pohlen
    Investigational New Drugs, 2009, 27 : 184 - 187
  • [38] The Effect of Blood Vessel Invasion on Prognosis of Operated Stage I Non-small Cell Lung Cancer Patients
    Turhan, K.
    Samancilar, O.
    Cagirici, U.
    Goksel, T.
    Nart, D.
    Cakan, A.
    Cok, G.
    THORACIC AND CARDIOVASCULAR SURGEON, 2010, 58 (01) : 28 - 31
  • [39] Effect of visceral pleural invasion on the prognosis of patients with lymph node negative non-small cell lung cancer
    Tian, Dan
    Pei, Yuquan
    Zheng, Qingfeng
    Zhang, Jianzhi
    Li, Shaolei
    Wang, Xing
    Lin, Dongmei
    Yang, Yue
    THORACIC CANCER, 2017, 8 (02) : 97 - 105
  • [40] Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer
    Shohei Hamada
    Hidenori Ichiyasu
    Tokunori Ikeda
    Megumi Inaba
    Kosuke Kashiwabara
    Tomoki Sadamatsu
    Nahoko Sato
    Kimitaka Akaike
    Hiroko Okabayashi
    Koichi Saruwatari
    Yusuke Tomita
    Sho Saeki
    Naomi Hirata
    Takeshi Yoshinaga
    Kazuhiko Fujii
    BMC Pulmonary Medicine, 19
12345